Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

68.87 +0.04 (+0.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,294,272
Open 68.09
Bid (Size) 68.06 (100)
Ask (Size) 70.44 (100)
Prev. Close 68.83
Today's Range 65.93 - 70.50
52wk Range 9.570 - 71.50
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+250.5%
+250.5%
1 Month
+72.8%
+72.8%
3 Month
+148.4%
+148.4%
6 Month
+305.8%
+305.8%
1 Year
+196.0%
+196.0%

More News

Read More
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
Via Stocktwits
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗
Via Stocktwits
News headline image
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗
Via Chartmill
News headline image
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
Via Benzinga
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Privium Fund Management Sells Into Strength in Pharma Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals
Via Business Wire
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗
Via The Motley Fool
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 68.87
When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 12/10/25 04:00 PM ET
What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 7.28B
How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
Arrowhead Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.